X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3727) 3727
Newspaper Article (99) 99
Book Chapter (43) 43
Magazine Article (11) 11
Newsletter (7) 7
Trade Publication Article (3) 3
Book / eBook (2) 2
Dissertation (2) 2
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2671) 2671
index medicus (2393) 2393
male (2339) 2339
prostate cancer (1473) 1473
androgens (1268) 1268
animals (1029) 1029
female (827) 827
prostatic neoplasms - drug therapy (817) 817
oncology (784) 784
testosterone (781) 781
androgen antagonists - therapeutic use (757) 757
cancer (691) 691
androgen receptor (664) 664
urology & nephrology (638) 638
care and treatment (619) 619
aged (601) 601
middle aged (583) 583
androgen antagonists - adverse effects (512) 512
endocrinology & metabolism (489) 489
research (477) 477
metastasis (461) 461
health aspects (441) 441
men (436) 436
prostatic neoplasms - pathology (427) 427
treatment outcome (404) 404
pharmacology & pharmacy (381) 381
prostate (372) 372
adult (366) 366
chemotherapy (347) 347
estrogen (337) 337
risk factors (329) 329
receptors, androgen - metabolism (326) 326
cancer therapies (320) 320
toxicology (320) 320
rats (316) 316
androgen deprivation therapy (313) 313
analysis (306) 306
medicine & public health (300) 300
hormones (289) 289
aged, 80 and over (286) 286
castration (285) 285
androgen-deprivation therapy (281) 281
urology (279) 279
mice (270) 270
antineoplastic agents, hormonal - therapeutic use (265) 265
therapy (264) 264
double-blind (252) 252
review (252) 252
clinical trials (251) 251
expression (241) 241
testosterone - blood (238) 238
drug therapy (236) 236
prostatic neoplasms - therapy (231) 231
antineoplastic agents - therapeutic use (230) 230
prostatic neoplasms - metabolism (220) 220
prostatic neoplasms, castration-resistant - drug therapy (220) 220
physiological aspects (216) 216
androgen (215) 215
orchiectomy (213) 213
abiraterone acetate (211) 211
quality of life (204) 204
patients (201) 201
androgen antagonists - pharmacology (200) 200
gene expression (199) 199
androgen antagonists - administration & dosage (197) 197
survival (197) 197
pregnancy (194) 194
studies (192) 192
development and progression (190) 190
docetaxel (190) 190
abridged index medicus (187) 187
tumors (187) 187
dose-response relationship, drug (185) 185
enzalutamide (185) 185
prostate-specific antigen - blood (183) 183
flutamide (181) 181
osteoporosis (181) 181
internal medicine (179) 179
prostate-cancer (176) 176
antineoplastic agents, hormonal - adverse effects (175) 175
metabolism (173) 173
disease progression (170) 170
quality-of-life (170) 170
receptors, androgen - genetics (166) 166
cell line, tumor (165) 165
androgens - metabolism (164) 164
gene-expression (164) 164
environmental sciences (163) 163
medicine (161) 161
metastases (160) 160
proteins (160) 160
radical prostatectomy (160) 160
apoptosis (159) 159
carcinoma (159) 159
abiraterone (158) 158
prognosis (157) 157
women (157) 157
postmenopausal women (155) 155
in-vitro (154) 154
antiandrogens (149) 149
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3844) 3844
German (32) 32
Japanese (21) 21
French (5) 5
Chinese (4) 4
Spanish (3) 3
Italian (2) 2
Polish (2) 2
Russian (2) 2
Afrikaans (1) 1
Croatian (1) 1
Danish (1) 1
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical cancer research, ISSN 1557-3265, 2013, Volume 19, Issue 19, pp. 5505 - 5512
Journal Article
Toxicological Sciences, ISSN 1096-6080, 03/2017, Volume 156, Issue 1, pp. 240 - 251
...), and thyroid hormone receptors (TRs). Furthermore, humans are commonly exposed simultaneously to complex mixtures of endocrine active compounds... 
Endocrine disruption | Cosmetic ingredients | Thyroid hormone receptor | Androgen receptor | Effects of mixtures | Glucocorticoid receptor | glucocorticoid receptor | PERSONAL CARE PRODUCTS | REPORTER GENE ASSAY | effects of mixtures | cosmetic ingredients | endocrine disruption | IN-VITRO | androgen receptor | thyroid hormone receptor | BISPHENOL-A | FLAME RETARDANTS | AGENTS | TOXICOLOGY | UV FILTERS | CELL-LINE | WATER | Receptors, Glucocorticoid - antagonists & inhibitors | Cosmetics - toxicity | Pituitary Gland - metabolism | Humans | Receptors, Glucocorticoid - metabolism | Receptors, Thyroid Hormone - antagonists & inhibitors | Dermatologic Agents - adverse effects | Androgen Receptor Antagonists - adverse effects | Resorcinols - adverse effects | Butylated Hydroxyanisole - toxicity | Glucocorticoids - metabolism | Female | Propiophenones - toxicity | Complex Mixtures - toxicity | Androgen Antagonists - toxicity | Antithyroid Agents - adverse effects | Butylated Hydroxyanisole - adverse effects | Rats | Mammary Glands, Animal - drug effects | Antithyroid Agents - toxicity | Complex Mixtures - adverse effects | Endocrine Disruptors - toxicity | Androgen Receptor Antagonists - toxicity | Receptors, Thyroid Hormone - metabolism | Endocrine Disruptors - adverse effects | Resorcinols - toxicity | Animals | Glucocorticoids - antagonists & inhibitors | Mammary Glands, Animal - metabolism | Propiophenones - adverse effects | Genes, Reporter - drug effects | Kinetics | Androgen Antagonists - adverse effects | Cell Line, Transformed | Pituitary Gland - drug effects
Journal Article
European Urology, ISSN 0302-2838, 2015, Volume 68, Issue 2, pp. 228 - 235
...) following docetaxel chemotherapy. Whether taxanes and next-generation androgen receptor (AR) axis inhibitors are cross-resistant or not is a subject of debate... 
Urology | Metastatic | Abiraterone | Prostate cancer | Cabazitaxel | ENZALUTAMIDE MDV3100 | CROSS-RESISTANCE | ANTITUMOR-ACTIVITY | CHEMOTHERAPY | PACLITAXEL | ANTIANDROGEN | UROLOGY & NEPHROLOGY | ABIRATERONE ACETATE | INCREASED SURVIVAL | RESISTANT PROSTATE-CANCER | CASTRATION-RESISTANT | Phenylthiohydantoin - adverse effects | Phenylthiohydantoin - therapeutic use | Humans | Middle Aged | Receptors, Androgen - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Molecular Targeted Therapy | Prostatic Neoplasms, Castration-Resistant - pathology | Dose-Response Relationship, Drug | Taxoids - therapeutic use | Receptors, Androgen - drug effects | Time Factors | Aged, 80 and over | Kallikreins - blood | Retrospective Studies | France | Taxoids - adverse effects | Cell Survival - drug effects | Androstenes - adverse effects | Kaplan-Meier Estimate | Androstenes - therapeutic use | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Prostatic Neoplasms, Castration-Resistant - metabolism | Phenylthiohydantoin - analogs & derivatives | Prostate-Specific Antigen - blood | Disease-Free Survival | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Androgen Antagonists - therapeutic use | Cell Line, Tumor | Aged | Cell Proliferation - drug effects | Prostatic Neoplasms, Castration-Resistant - mortality | Androgen Antagonists - adverse effects
Journal Article
The New England journal of medicine, ISSN 0028-4793, 2019, Volume 381, Issue 1, pp. 13 - 24
A randomized trial tested whether the addition of apalutamide, an androgen receptor blocker, to androgen-deprivation therapy might improve radiographic... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | THERAPY | ANTIANDROGEN | FUNCTIONAL ASSESSMENT | QUALITY-OF-LIFE | DOCETAXEL | Adenocarcinoma - pathology | Androgen Receptor Antagonists - therapeutic use | Humans | Middle Aged | Male | Androgen Receptor Antagonists - adverse effects | Thiohydantoins - adverse effects | Neoplasm Grading | Exanthema - chemically induced | Thiohydantoins - therapeutic use | Aged, 80 and over | Adult | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Double-Blind Method | Kaplan-Meier Estimate | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Prostatic Neoplasms - mortality | Radiography | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Androgen Antagonists - therapeutic use | Quality of Life | Aged | Androgen Antagonists - adverse effects | Adenocarcinoma - mortality | Treatment outcome | Development and progression | Drug therapy | Prostate cancer | Analysis | Nuclear magnetic resonance--NMR | Medical imaging | Research & development--R&D | Clinical trials | Oncology | Metastasis | Radiation therapy | Patients | Cancer therapies | Survival | Evidence-based medicine | Metastases | Androgens | Chemotherapy | Pain | Castration | Pharmaceuticals | Urologi och njurmedicin | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Urology and Nephrology
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 5, pp. 424 - 433
Journal Article
European Urology, ISSN 0302-2838, 03/2019, Volume 75, Issue 3, pp. 368 - 373
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 367, Issue 13, pp. 1187 - 1197
Journal Article
Cancer cell, ISSN 1535-6108, 2010, Volume 17, Issue 6, pp. 535 - 546
Castration-recurrent prostate cancer (CRPC) is suspected to depend on androgen receptor (AR... 
CELLCYCLE | CROSS-TALK | SIGNAL-TRANSDUCTION PATHWAYS | STEROID-BINDING | ONCOLOGY | INDEPENDENT TRANSCRIPTIONAL ACTIVATION | NUCLEAR RECEPTORS | CREB-BINDING-PROTEIN | FACTORS INDUCE | BISPHENOL-A | PROLIFERATION | EXPRESSION | CELL BIOLOGY | Protein Binding - genetics | Apoptosis - drug effects | Humans | Protein Conformation - drug effects | Transcriptional Activation - drug effects | Male | Neoplasm Recurrence, Local - pathology | Antineoplastic Agents, Hormonal - adverse effects | CREB-Binding Protein - metabolism | Prostate - pathology | Protein Binding - drug effects | Serine Endopeptidases - genetics | Prostate - drug effects | Prostate-Specific Antigen - metabolism | Benzhydryl Compounds - therapeutic use | Prostatic Neoplasms - drug therapy | Chlorohydrins - therapeutic use | Prostate-Specific Antigen - genetics | Prostate - anatomy & histology | DNA - metabolism | Prostate-Specific Antigen - blood | Androgens - pharmacology | Cell Line, Tumor | Ligands | Mice, Inbred NOD | Mice | Protein Multimerization - drug effects | Androgen Receptor Antagonists | Gene Expression - drug effects | Receptors, Androgen - metabolism | Neoplasm Recurrence, Local - drug therapy | Benzhydryl Compounds - adverse effects | Castration | Antineoplastic Agents, Hormonal - therapeutic use | Molecular Structure | Response Elements - genetics | Chlorohydrins - pharmacology | Chlorohydrins - adverse effects | Prostatic Neoplasms - pathology | Antineoplastic Agents, Hormonal - pharmacology | Prostatic Neoplasms - surgery | Protein Interaction Domains and Motifs - drug effects | Receptors, Steroid - drug effects | Mice, SCID | DNA - genetics | Xenograft Model Antitumor Assays | Animals | Benzhydryl Compounds - pharmacology | Cell Proliferation - drug effects | Chemical oceanography | Prostate cancer | Index Medicus
Journal Article
Breast cancer research and treatment, ISSN 1573-7217, 2018, Volume 171, Issue 1, pp. 111 - 120
Journal Article